Lv3
292 积分 2026-02-04 加入
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
16天前
已完结
Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer
16天前
已完结
Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma
16天前
已关闭
Oncorine, the World First Oncolytic Virus Medicine and its Update in China
16天前
已完结
Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies
16天前
已完结
Oncolytic virus VG161 in refractory hepatocellular carcinoma
16天前
已完结
Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors
1个月前
已关闭
LRRC15-CAR T cells for the treatment of osteosarcoma
7个月前
已完结
Measuring T-cell/CAR T-cell bystander tumor killing in vitro and in vivo
7个月前
已完结
Optimizing In Vivo CAR-T Cell Engineering for Cancer Immunotherapy
7个月前
已完结
皖公网安备34019202002308
